日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Clinical and Molecular Validation of the Very Favorable IMDC Risk Group in Metastatic Renal Cell Carcinoma

转移性肾细胞癌中IMDC风险组极佳预后的临床和分子验证

Zarba, Martin; Saad, Eddy; Semaan, Karl; El Zarif, Talal; Ferrier, Evan; Wells, Connor; El Hajj Chehade, Razane; Basappa, Naveen S; Ebrahimi, Hedyeh; Huseni, Mahrukh; Banchereau, Romain; McKay, Rana R; Wood, Lori; Beuselinck, Benoit; Suárez, Cristina; Takemura, Kosuke; Lalani, Aly-Khan A; Li, Haoran; Spain, Lavinia Anne; Templeton, Arnoud J; Powles, Thomas B; Bjarnason, Georg A; de Velasco, Guillermo; Choueiri, Toni K; Heng, Daniel Y C

CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy

CONTACT-01:一项随机 III 期试验,比较阿特珠单抗联合卡博替尼与多西他赛治疗接受过免疫检查点抑制剂和化疗后的转移性非小细胞肺癌的疗效

Neal, Joel; Pavlakis, Nick; Kim, Sang-We; Goto, Yasushi; Lim, Sun Min; Mountzios, Giannis; Fountzilas, Elena; Mochalova, Anastasia; Christoph, Daniel C; Bearz, Alessandra; Quantin, Xavier; Palmero, Ramon; Antic, Vladan; Chun, Elaine; Edubilli, Tirupathi Rao; Lin, Ya-Chen; Huseni, Mahrukh; Ballinger, Marcus; Graupner, Vilma; Curran, Dominic; Vervaet, Piet; Newsom-Davis, Thomas

CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy

CD8+ T 细胞内在的 IL-6 信号传导促进对 PD-L1 抗免疫疗法的耐药性

Mahrukh A Huseni ,Lifen Wang ,Joanna E Klementowicz ,Kobe Yuen ,Beatrice Breart ,Christine Orr ,Li-Fen Liu ,Yijin Li ,Vinita Gupta ,Congfen Li ,Deepali Rishipathak ,Jing Peng ,Yasin Şenbabaoǧlu ,Zora Modrusan ,Shilpa Keerthivasan ,Shravan Madireddi ,Ying-Jiun Chen ,Eleanor J Fraser ,Ning Leng ,Habib Hamidi ,Hartmut Koeppen ,James Ziai ,Kenji Hashimoto ,Marcella Fassò ,Patrick Williams ,David F McDermott ,Jonathan E Rosenberg ,Thomas Powles ,Leisha A Emens ,Priti S Hegde ,Ira Mellman ,Shannon J Turley ,Mark S Wilson ,Sanjeev Mariathasan ,Luciana Molinero ,Mark Merchant ,Nathaniel R West

CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy

CD8+ T 细胞内在的 IL-6 信号传导促进对 PD-L1 抗免疫疗法的耐药性

Mahrukh A Huseni,Lifen Wang,Joanna E Klementowicz,Kobe Yuen,Beatrice Breart,Christine Orr,Li-Fen Liu,Yijin Li,Vinita Gupta,Congfen Li,Deepali Rishipathak,Jing Peng,Yasin Şenbabaoǧlu,Zora Modrusan,Shilpa Keerthivasan,Shravan Madireddi,Ying-Jiun Chen,Eleanor J Fraser,Ning Leng,Habib Hamidi,Hartmut Koeppen,James Ziai,Kenji Hashimoto,Marcella Fassò,Patrick Williams,David F McDermott,Jonathan E Rosenberg,Thomas Powles,Leisha A Emens,Priti S Hegde,Ira Mellman,Shannon J Turley,Mark S Wilson,Sanjeev Mariathasan,Luciana Molinero,Mark Merchant,Nathaniel R West

Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma

IMmotion151 是一项 3 期临床试验,比较了阿特珠单抗联合贝伐珠单抗与舒尼替尼治疗既往未接受治疗的转移性肾细胞癌患者的疗效,本研究的最终总生存期和分子分析结果如下:

Motzer, Robert J; Powles, Thomas; Atkins, Michael B; Escudier, Bernard; McDermott, David F; Alekseev, Boris Y; Lee, Jae-Lyun; Suarez, Cristina; Stroyakovskiy, Daniil; De Giorgi, Ugo; Donskov, Frede; Mellado, Begoña; Banchereau, Romain; Hamidi, Habib; Khan, Omara; Craine, Veronica; Huseni, Mahrukh; Flinn, Nick; Dubey, Sarita; Rini, Brian I

First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors

OX40激动剂MOXR0916治疗晚期实体瘤患者的首次人体I期研究

Kim, Tae Won; Burris, Howard A; de Miguel Luken, Maria J; Pishvaian, Michael J; Bang, Yung-Jue; Gordon, Michael; Awada, Ahmad; Camidge, D Ross; Hodi, F Stephen; McArthur, Grant A; Miller, Wilson H; Cervantes, Andres; Chow, Laura Q; Lesokhin, Alexander M; Rutten, Annemie; Sznol, Mario; Rishipathak, Deepali; Chen, Shang-Chiung; Stefanich, Eric; Pourmohamad, Tony; Anderson, Maria; Kim, Jeong; Huseni, Mahrukh; Rhee, Ina; Siu, Lillian L

Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial

在IMmotion150研究中,阿特珠单抗联合贝伐珠单抗治疗在阿特珠单抗或舒尼替尼单药治疗后疾病进展的转移性肾细胞癌患者的疗效和安全性:一项随机II期临床试验

Powles, Thomas; Atkins, Michael B; Escudier, Bernard; Motzer, Robert J; Rini, Brian I; Fong, Lawrence; Joseph, Richard W; Pal, Sumanta K; Sznol, Mario; Hainsworth, John; Stadler, Walter M; Hutson, Thomas E; Ravaud, Alain; Bracarda, Sergio; Suarez, Cristina; Choueiri, Toni K; Reeves, James; Cohn, Allen; Ding, Beiying; Leng, Ning; Hashimoto, Kenji; Huseni, Mahrukh; Schiff, Christina; McDermott, David F

Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade

肾癌分子亚型决定免疫检查点和血管生成阻断疗法的疗效

Motzer, Robert J; Banchereau, Romain; Hamidi, Habib; Powles, Thomas; McDermott, David; Atkins, Michael B; Escudier, Bernard; Liu, Li-Fen; Leng, Ning; Abbas, Alexander R; Fan, Jinzhen; Koeppen, Hartmut; Lin, Jennifer; Carroll, Susheela; Hashimoto, Kenji; Mariathasan, Sanjeev; Green, Marjorie; Tayama, Darren; Hegde, Priti S; Schiff, Christina; Huseni, Mahrukh A; Rini, Brian

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

阿特珠单抗单药或联合贝伐珠单抗与舒尼替尼治疗肾细胞癌的临床活性及分子相关性

McDermott, David F; Huseni, Mahrukh A; Atkins, Michael B; Motzer, Robert J; Rini, Brian I; Escudier, Bernard; Fong, Lawrence; Joseph, Richard W; Pal, Sumanta K; Reeves, James A; Sznol, Mario; Hainsworth, John; Rathmell, W Kimryn; Stadler, Walter M; Hutson, Thomas; Gore, Martin E; Ravaud, Alain; Bracarda, Sergio; Suárez, Cristina; Danielli, Riccardo; Gruenwald, Viktor; Choueiri, Toni K; Nickles, Dorothee; Jhunjhunwala, Suchit; Piault-Louis, Elisabeth; Thobhani, Alpa; Qiu, Jiaheng; Chen, Daniel S; Hegde, Priti S; Schiff, Christina; Fine, Gregg D; Powles, Thomas

Phenotypical characterization of human rhinovirus infections in severely premature children

严重早产儿鼻病毒感染的表型特征

Perez, Geovanny F; Kurdi, Bassem; Megalaa, Rosemary; Pancham, Krishna; Huseni, Shehlanoor; Isaza, Natalia; Rodriguez-Martinez, Carlos E; Pillai, Dinesh; Nino, Gustavo